-
1.发明公开SELECTIVE DIFFERENTIATION, IDENTIFICATION, AND MODULATION OF HUMAN TH17 CELLS 有权选择性分化，鉴定及人Th17细胞的调节作用
公开(公告)号：EP2238241A2
公开(公告)日：2010-10-13
申请号：EP09702239.6
申请日：2009-01-21
CPC分类号： C12N5/0636 , A61K2039/57 , C12N2501/15 , C12N2501/23 , G01N33/505 , G01N2333/4728 , G01N2333/495 , G01N2333/54 , G01N2333/705 , G01N2800/065 , G01N2800/102 , G01N2800/122 , G01N2800/205 , G01N2800/24 , G01N2800/285
摘要： The embodiments provide for the modulation of both the differentiation and activity of human TH17 cells. More specifically, human TH17 cell differentiation can modulated by TGF-? and IL-21, and their agonists and antagonists. Function of TH17 cells can be modulated by, for example, BLT1 or podoplanin, and their agonists and antagonists. Additionally, the embodiments provide for the identification of TH17 cells. More specifically, human TH17 cells specifically upregulate BLT1 and podoplanin.
-
公开(公告)号：EP4091631A1
公开(公告)日：2022-11-23
申请号：EP21197088.4
申请日：2003-01-30
发明人： KUCHROO, Vijay K. , MONNEY, Laurent , GREENFIELD, Edward , GAGLIA, Jason , FREEMAN, Gordon , WALDNER, Hanspeter
IPC分类号： A61K39/395 , C07K16/28
摘要： The present invention provides compositions and methods useful for promoting or reducing T-cell trafficking to a target tissue. Also provided are compositions and methods useful for promoting or inhibiting antigen-presenting cell (APC) activation. The invention is related to discovery of functional characteristics of TIM-3, a molecule that is preferentially expressed on the surface of Thl cells. The methods are useful for treating disorders including cancer, infectious disease, allergy, asthma, and autoimmune disease.
-
3.发明授权SELECTIVE DIFFERENTIATION, IDENTIFICATION, AND MODULATION OF HUMAN TH17 CELLS 有权选择性分化，鉴定及人Th17细胞的调节作用
公开(公告)号：EP2238241B1
公开(公告)日：2013-09-11
申请号：EP09702239.6
申请日：2009-01-21
CPC分类号： C12N5/0636 , A61K2039/57 , C12N2501/15 , C12N2501/23 , G01N33/505 , G01N2333/4728 , G01N2333/495 , G01N2333/54 , G01N2333/705 , G01N2800/065 , G01N2800/102 , G01N2800/122 , G01N2800/205 , G01N2800/24 , G01N2800/285
-
公开(公告)号：EP2879709B1
公开(公告)日：2020-01-08
申请号：EP13826181.3
申请日：2013-07-30
IPC分类号： C07K14/705 , C07K7/08 , A61K39/00 , A61K38/10 , A61K39/395 , C07K16/28 , C07K16/30
-
公开(公告)号：EP3377086A1
公开(公告)日：2018-09-26
申请号：EP16816778.1
申请日：2016-11-17
申请人： The Brigham and Women's Hospital, Inc. , The Broad Institute Inc. , Massachusetts Institute Of Technology
发明人： KUCHROO, Vijay K. , WANG, Chao , REGEV, Aviv , SHEKHAR, Karthik
CPC分类号： C07K14/70596 , A61K38/1709 , A61K38/177 , A61K38/208 , A61K39/3955 , A61K45/06 , A61K2039/575 , A61P1/00 , A61P35/00 , A61P37/00 , C07K14/5434 , C07K16/244 , C07K16/2896 , C12N15/1136 , C12N15/1138 , C12N2310/11 , C12N2310/14 , C12N2310/20
摘要： Described herein are methods for suppressing an immune response in a subject, e.g., a subject with an autoimmune disease, by administering to the subject a therapeutically effective amount of recombinant CD5L, CD5L homodimers and/or CD5L:p40 heterodimers, or nucleic acids encoding any of these. Also described are methods for enhancing an immune response in a subject, e.g., a subject with cancer, infection, or an immune deficiency, by administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds specifically to CD5L, D5L homodimers and/or CD5L:p40 heterodimers, and inhibits their binding to the IL-23 receptor, or inhibits formation of the CD5L homodimer and/or CD5L:p40 heterodimer, or inhibitory nucleic acids that target CD5L and/or p40.
-
公开(公告)号：EP2081961A2
公开(公告)日：2009-07-29
申请号：EP07867488.4
申请日：2007-11-15
IPC分类号： C07K16/28
CPC分类号： C07K14/705 , A01K2227/105 , A01K2267/0387 , C07K16/28 , C07K2317/75
摘要： The invention provides novel methods of treating neurological disorders, including neurodegenerative disorders such as MS. The invention also provides novel methods of treating cancers, including glial tumors such as glioblastoma multiforme. The invention further provides vaccines and related uses.
-
公开(公告)号：EP2879709A1
公开(公告)日：2015-06-10
申请号：EP13826181.3
申请日：2013-07-30
IPC分类号： A61K39/395 , A61K48/00 , C07K14/00 , A61P37/02 , A61P37/04
摘要： Described herein are compositions and methods for the modulation of T-cell tolerance, which can be upregulated or down regulated by concurrent enhancement or inhibition of CEACAM1/TIM3 interactions. As described herein, the discovery that CEACAM1 is a direct ligand of TIM3 and vice versa has been shown in cis and in trans. In addition, as demonstrated herein, CEACAM1 and TIM3 are co-regulated during the course of T-cell activation.
-
8.发明公开MODULATION OF SGK1 EXPRESSION IN TH17 CELLS TO MODULATE TH17-MEDIATED IMMUNE RESPONSES 审中-公开调制剂SGK1-表达BEI TH17-ZELLEN ZUR MODULATION VON TH17-VERMITTELTEN IMMUNREAKINGEN
公开(公告)号：EP2459184A1
公开(公告)日：2012-06-06
申请号：EP10740108.5
申请日：2010-07-30
发明人： KUCHROO, Vijay K. , JIN, Hulin
IPC分类号： A61K31/015 , A61K31/404 , A61K31/437 , A61P37/00
CPC分类号： A61K31/404 , A61K31/407 , A61K31/437 , A61K39/39 , A61K2039/55511 , A61K2039/57 , Y02A50/386 , Y02A50/388
摘要： The inventors have made the surprising discovery that SGK1, a serine/threonine kinase previously described as being involved in regulation of cellular sodium homeostasis, has a novel and unexpected function in the differentiation and function of a specific subset of CD4 T cells, the TH17 lineage. Described herein are methods and compositions for modulation of TH17 cell differentiation, proliferation, and/or function that rely upon modulating the activity or expression of SGK1. Such methods and compositions are useful in the treatment of disorders including autoimmune diseases, chronic inflammatory conditions, infectious diseases, and cancer.
摘要翻译： 本发明人已经令人惊奇地发现，SGK1（丝氨酸/苏氨酸激酶以前被描述为参与细胞钠稳态调节）在CD4T细胞特异性子集的分化和功能中具有新颖和意想不到的功能，TH17谱系 。 本文描述了用于调节依赖于调节SGK1的活性或表达的TH17细胞分化，增殖和/或功能的方法和组合物。 这些方法和组合物可用于治疗包括自身免疫性疾病，慢性炎性病症，感染性疾病和癌症的疾病。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.023 秒)
